Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2011

Feb 22, 2011

30016_dirs_2011-02-22_cf9ba8a2-630f-4593-aaa4-39a0f4a8dfd3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2011-02-17

Reporting Person: POLEWACZYK JAMES F (Corporate Vice President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-02-17 Common Stock M 5265 $56.9500 Acquired 8272 Direct
2011-02-17 Common Stock M 8000 $34.37 Acquired 16272 Direct
2011-02-17 Common Stock M 2000 $53.31 Acquired 18272 Direct
2011-02-17 Common Stock M 3603 $56.95 Acquired 21875 Direct
2011-02-17 Common Stock S 12000 $77.5764 Disposed 9875 Direct
2011-02-17 Common Stock S 5236 $77.6623 Disposed 4639 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-02-17 Incentive Stock Option (right to buy) $56.95 M 5265 Disposed 2015-02-13 Common Stock (5265) Direct
2011-02-17 Non-Qualified Stock Option (right to buy) $34.37 M 8000 Disposed 2016-02-13 Common Stock (8000) Direct
2011-02-17 Non-Qualified Stock Option (right to buy) $53.31 M 2000 Disposed 2017-02-13 Common Stock (2000) Direct
2011-02-17 Non-Qualified Stock Option (right to buy) $56.95 M 3603 Disposed 2015-02-13 Common Stock (3603) Direct

Footnotes

F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.50 to $77.72, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.63 to $77.695, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

F3: Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.

F4: Grant of options to buy shares of common stock becomes exercisable as to 4,149 shares on 02/14/2010, 02/14/2011, 02/14/2012, 02/14/2013, and the remaining 1,241 shares on 02/14/2014.

F5: Grant of options to buy shares of common stock becomes exercisable as to 2,707 shares on 02/14/2011 and 02/14/2012, 2,706 shares on 02/14/2013 and 02/14/2014, and the remaining 831 shares on 02/14/2015.

F6: Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.